title: [Results of acute myeloid leukemia treatment. Analysis of 63 patients between 2010-2014].
abstract: BACKGROUND
  Acute myeloid leukemia (AML) is the most common acute leukemia in adults, emphasizing its high recurrence rate despite hematopoietic cell transplantation (HCT).
  
  
  OBJECTIVE
  To report the results of AML treatment at the Catholic University of Chile Clinical Hospital.
  
  
  METHODS
  Review of medical records of patients with AML.
  
  
  RESULTS
  63 patients, median age 55.4 years (range:16-89), treated between 2010 and 2014. Admission laboratory values showed (median values): leukocytes 45.989/mm³, hemoglobin 9.1 g/dl, platelets 75.548/mm³, peripheral blood blasts 38% and bone marrow blasts 74%. According to cytogenetic risk classification we observed the following groups: favorable 8% (n = 5), intermediate 51% (n = 32), unfavorable 13% (n = 8) and unknown 28% (n = 17). Seventy five percent of patients received induction chemotherapy and 25% palliative care. Median survival of treated and palliative care patients was 27.3 and 1 month respectively. Induction chemotherapy (IC) mortality (ICM) was 4.2%. Seventy percent (n = 33) of patients who received IC had complete response (CR) with a 3-year relapse free survival (RFS) of 25% and overall survival (OS) of 31%. Multivariate analysis demonstrated that achievement of CR, cytogenetic risk group and receiving consolidation chemotherapy were significantly associated with better RFS and OS.
  
  
  CONCLUSIONS
  AML treatment with standard chemotherapy in our center achieves similar results to what has been described in international series regarding induction rates and ICM, however RFS and OS are still very low, especially in intermediate and high cytogenetic risk groups.
authors.forename: Mónica
authors.initials: M
authors.lastname: Fuentes
authors.forename: Patricio
authors.initials: P
authors.lastname: Rojas
authors.forename: Daniel
authors.initials: D
authors.lastname: Ernst
authors.forename: Mauricio
authors.initials: M
authors.lastname: Ocqueteau
authors.forename: Pablo
authors.initials: P
authors.lastname: Bertin
authors.forename: Mauricio
authors.initials: M
authors.lastname: Sarmiento
authors.forename: Pablo
authors.initials: P
authors.lastname: Ramírez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002677:Chile; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult